Inflammaging and Degenerative Joint Disease
Today I want to share with you an article which appeared today in the weekly Fight Aging newsletter.
The Fight Aging newsletter is free and is published and sent out weekly on Sundays.
It is the best source I know of as a summary of current developments in the area of aging research.
This article discusses the concept that age-related degeneration of joints – specifically cartilage is associated with inflammation, which I am sure for most of you is a well known basic concept.
It mentions two key concepts: the Inflammasome as well as Cellular Senescence.
If you are not familiar with the concept of the Inflammasome I have included a link and abstract from a paper published in Nature at the end of this article.
Regarding cellular senescence, I have previously written an article on this topic in October of last year –
Here is a link to the article if you want to review it.
Cellular senescence has been identified as a key factor contributing to the aging process, and it is a key target for both big Pharma as well as Biotech companies to develop compounds which target and destroy senescent cells – referred to as “Senolytics”.
There are currently human drug trials being conducted with senolytic compounds to target senesecent cells (sometimes referred to as “zombie cells” in the common literature) and I am of the opinion that awareness of this concept will be well established within the general population within probably 12 – 24 months – and I don’t think there is any doubt that health care practitioners across the spectrum will be utilizing senolytic compounds in their practice to target age related degenerative conditions.
Our Activity Relating to Senolytics
I have been extensively researching this topic of cellular senescence and senolytic compounds for approximately two years now and our company is in the final stages of application preparation for an NPN for a natural source senolytic formulation,
so hopefully within about six months or so we will have our formulation approved such that we can bring it to the market:
I will provide you with further information on this topic as we progress towards our product launch.
To my knowledge, at this stage there are no specific natural compound formulations which target cellular senescence – anywhere in the world.
Following is the article: one key takeaway from this article and additional reading I have done on this topic is that senolytic compounds may provide a key approach to arthritic conditions.
